Laboratory equipment market seen doubling by 2035

Market Research Future projects the global laboratory equipment market will grow from $38.09 billion in 2026 to $77.42 billion by 2035, driven by biopharmaceutical R&D, rising chronic disease testing and automation. Asia-Pacific is expected to lead growth as hospitals, research labs and drug developers expand capacity.

Why it matters: - The laboratory equipment market is moving from a hardware replacement cycle to a recurring consumables and software model. - That shift affects drug development, hospital diagnostics and research infrastructure across major markets. - The forecast points to stronger demand for automation, single-use systems and integrated lab platforms through 2035.

What happened: - Market Research Future projects the global laboratory equipment market will rise from $38.09 billion in 2026 to $77.42 billion by 2035. - The forecast implies an 8.2% compound annual growth rate from 2026 to 2035. - The market was estimated at $35.20 billion in 2025. - The report frames growth around biopharmaceutical spending, chronic disease burden and lab automation. - A free sample is available here. - The full report is available here.

The details: - Global biopharmaceutical R&D spending crossed $205 billion in 2024. - The World Health Organization says non-communicable diseases cause about 41 million deaths each year, or 74% of all fatalities. - The U.S. National Institutes of Health allocates more than $47 billion annually. - The 21st Century Cures Act continues to support biomarker-driven trial designs. - China requires county-level hospitals to obtain ISO 15189 accreditation by 2027, a move estimated to generate more than $3.5 billion in equipment purchases. - Japan’s MHLW expanded reimbursement codes for automated molecular diagnostics in 2024. - Single-use bioreactor linings, pre-sterilized pipette tips and disposable filtration assemblies are shortening replacement cycles from five years to under two in biomanufacturing. - North America and Europe are leading single-use adoption, with penetration expected to reach 68% of upstream bioprocess operations by 2030. - Legacy benchtop workflows are giving way to integrated systems that combine sample preparation, analysis and data management. - Public-sector net-zero mandates are also pushing suppliers toward low-carbon manufacturing and take-back programs.

Between the lines: - The market is becoming more consumables-heavy, which should boost recurring revenue for suppliers even if hardware replacement slows. - Hospital consolidation and pooled procurement may expand access while pressuring margins. - The strongest demand is likely to come from markets with large research budgets, reimbursement support and mandatory lab accreditation. - AI and automation are emerging as the next competitive layer, not just throughput improvements.

What's next: - Asia-Pacific is expected to remain the fastest-growing region at 9.2% CAGR from 2026 to 2035. - China, India and Japan are set to drive much of that growth through hospital upgrades, biopharma spending and diagnostic modernization. - By 2030, fully autonomous laboratories could handle up to 40% of routine assay workflows in high-throughput settings. - Embedded machine learning in lab instruments is expected to support calibration, anomaly detection and predictive maintenance. - Early adopters report 25% less unplanned downtime, suggesting software and service contracts may become a larger revenue stream.

The bottom line: - Laboratory equipment is evolving into a platform business tied to diagnostics, drug development and automation, with growth likely to be strongest where governments and health systems are forcing modernization.